Catalyst Wire Dossier Catalyst Wire Dossier

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), covering 2022-12-20 to 2022-12-20. Get the full timeline:

Most recent: Clinical Trial Update: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE [Phase 4]

See pricing